Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.
Muthiah VaduganathanCatherine M ViscoliNaveed SattarDavid H FitchettAnne Pernille OfstadMartina BrueckmannJyothis T GeorgeSubodh VermaMichaela MattheusChristoph WannerBernard ZinmanJaved ButlerPublished in: Diabetes, obesity & metabolism (2021)
In patients with type 2 diabetes and cardiovascular disease, empagliflozin markedly and durably delays insulin initiation and substantial increases in insulin dose, while facilitating sustained reductions in insulin requirements over time.